$ABVX
Fibrosis data from ECCO 26 (Abstract OP30):
In vivo (mice): ~52% reduction in collagen (early), ~42% (late) vs ~24% control.
In vitro (human cells): 50% reduction in PRO-C3; active in pathways where Nintedanib showed no activity.
Stat sig: p < 0.0001 for key markers.
@Oligo_bio Now I don’t know his current net worth, but no rational human being risks a guaranteed $200 million fortune on the hopes that a drug launch goes perfectly in 2027…
@plantmath1 It’s not over. Many names in Europe still setting up. It’s just starting to dawn on everyone that decoupling from the US shouldn’t be a process, it has to happen ASAP.
Being contrarian for the sake of being contrarian is not a thesis. Some of my greatest hits seemed too good to be true initially, like $RKLB at 3 billion mcap.
Mindless pumpers don’t just pump gme or amc, they pump great companies, too. Best to just ignore them.
$ABVX
I see too much hype with $abvx. Everyone is saying it’s going to get bought out at $200 a share and these unrealistic prices. I don’t think the system is going to let people make money this easy. When people say it’s too good to be true, it is too good to be true (for 98% of the time). I wouldn’t be surprised if this is all a dud.